Overview

Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer

Status:
Not yet recruiting

Trial end date:
2030-11-01

Target enrollment:

Participant gender:

Summary

This study evaluates the interest of regorafenib in combination of metronomic chemotherapies and low-dose aspirin as a 2 months induction therapy before chemotherapy initiation in the second-line metastatic colorectal carcinoma

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Centre Hospitalier Universitaire de Besancon

Treatments:

Aspirin
Bevacizumab